These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28591104)

  • 21. Treatment for myeloma bone disease.
    Yeh HS; Berenson JR
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6279s-6284s. PubMed ID: 17062714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Bone lesion in multiple myeloma].
    Ise M; Takagi T
    Nihon Rinsho; 2007 Dec; 65(12):2224-8. PubMed ID: 18069264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic approaches to myeloma bone disease: an evolving story.
    Longo V; Brunetti O; D'Oronzo S; Dammacco F; Silvestris F
    Cancer Treat Rev; 2012 Oct; 38(6):787-97. PubMed ID: 22494965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myeloma bone disease.
    Berenson JR
    Best Pract Res Clin Haematol; 2005; 18(4):653-72. PubMed ID: 16026743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myeloma bone disease.
    Sezer O
    Hematology; 2005; 10 Suppl 1():19-24. PubMed ID: 16188625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloma and bone disease: "the dangerous tango".
    Epstein J; Walker R
    Clin Adv Hematol Oncol; 2006 Apr; 4(4):300-6. PubMed ID: 16728940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment strategies for bone disease.
    Roodman GD
    Bone Marrow Transplant; 2007 Dec; 40(12):1139-46. PubMed ID: 17680018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of multiple myeloma bone disease: impact of treatment on renal function.
    Kanellias N; Gavriatopoulou M; Terpos E; Dimopoulos MA
    Expert Rev Hematol; 2018 Nov; 11(11):881-888. PubMed ID: 30285492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel therapeutic targets in myeloma bone disease.
    Webb SL; Edwards CM
    Br J Pharmacol; 2014 Aug; 171(16):3765-76. PubMed ID: 24750110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New agents in the Treatment of Myeloma Bone Disease.
    Ring ES; Lawson MA; Snowden JA; Jolley I; Chantry AD
    Calcif Tissue Int; 2018 Feb; 102(2):196-209. PubMed ID: 29098361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Management of bone lesions in multiple myeloma].
    Hata H; Mitsuya H
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1072-6. PubMed ID: 16912524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Management of bone disease in multiple myeloma].
    Izumi T
    Gan To Kagaku Ryoho; 2012 Aug; 39(8):1187-90. PubMed ID: 22902442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloma Bone Disease: A Comprehensive Review.
    Mukkamalla SKR; Malipeddi D
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Proteasome and Myeloma-Associated Bone Disease.
    Accardi F; Toscani D; Costa F; Aversa F; Giuliani N
    Calcif Tissue Int; 2018 Feb; 102(2):210-226. PubMed ID: 29080972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myeloma bone disease: Progress in pathogenesis.
    Xi H; An R; Li L; Wang G; Tao Y; Gao L
    Prog Biophys Mol Biol; 2016 Nov; 122(2):149-155. PubMed ID: 27496181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenesis of myeloma bone disease.
    Roodman GD
    Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathophysiology of multiple myeloma bone disease.
    Lentzsch S; Ehrlich LA; Roodman GD
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myeloma bone disease: recent advances in biology, diagnosis, and treatment.
    Sezer O
    Oncologist; 2009 Mar; 14(3):276-83. PubMed ID: 19286761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
    Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
    Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.